Почетна › Немалоклетни карцином плућа › Тенеси
Kliničke studije za Немалоклетни карцином плућа u državi Тенеси
120 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Тенеси.
Gradovi u državi Тенеси
Zvanični tekst studije (na engleskom)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Regional One Health, Memphis
- Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 13. 11. 2026. · NCT05920356Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Tennessee Oncology, Nashville
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07100080Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- University Cancer Specialists - Alcoa, Alcoa
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Tennessee Oncology - Chattanooga - Downtown, Chattanooga
- Tennessee Oncology - Chattanooga - GHCR Site I, Chattanooga
- Tennessee Oncology - Chattanooga - Memorial Plaza, Chattanooga
- и још 6
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06472245Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Sarah Cannon Research Institute-Nashville-48456, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04886804A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06914128A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07020221A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- University of Tennessee Medical Center Knoxville ( Site 0082), Knoxville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06312137Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT04557449A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07503808Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Local Institution - 0199, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07680790Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07291037A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315), Chattanooga
- Thompson Cancer Survival Center ( Site 0168), Knoxville
- Baptist Clinical Research Institute, Inc. ( Site 9501), Memphis
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06623422A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- The University of Tennessee Medical Center ( Site 3223), Knoxville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07513376A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Baptist Clinical Research Institute, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07541170Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- University of Tennessee Health Science Center, Knoxville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT04198766A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Baptist Cancer Center, Bartlett
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- и још 18
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07144280A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07090499A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Baptist Cancer Center, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07361497A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Tennessee Oncology Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06890598A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06150664A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Sarah Cannon Research Institute, LLC, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital for Women, Memphis
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute - Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07857616A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Tennessee Oncology Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Baptist Memorial Hospital-Memphis, Memphis
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07397338A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06695845A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06667076A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07542704A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07293247A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07903415Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Tennessee Oncology - Nashville St. Thomas Midtown Clinic, Nashville
- Tennessee Oncology Nashville - SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07288177A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Tennessee Oncology, Nashville
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07365319Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- University of Tennessee Medical Center, Knoxville
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06712316Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Tennessee Oncology, Nashville
- Vanderbilt - Ingram Cancer Center, Nashville
Тражи се учесникФаза 3
Узраст од 18 до 90 · Оба пола · Ажурирано 2. 11. 2026. · NCT06745908Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.